Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normobaric Nocturnal Hyperoxia for Retinal Ischemia
NCT03730779Phase 4Withdrawn
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2018
- Primary completion
- Jan 2020
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxygen in retinal ischemia, sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Best Corrected Visual Acuity at 6 months and Macula Edema at 6 months. Planned start Nov 2018; status: withdrawn.
02
Drugs
oxygen
03
Conditions
retinal ischemia
Beyond the preview
Go deeper on NCT03730779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730779.